Priya Marathe 医学博士(美国纽约纪念斯隆-凯特琳癌症中心)

Priya Marathe 医学博士(美国纽约纪念斯隆-凯特琳癌症中心)
获奖年份: 2025
金额: $60,000
研究时长: 2年
Dr. Priya Marathe was awarded $60,000 to conduct a two-year study examining disparities in Erdheim–Chester Disease diagnosis and treatment with respect to race and socioeconomic status. The study will use a multi-institutional cohort to measure differences in care and expand the MSK-BRIDGE program to improve access to expert care and clinical trials for underrepresented patients.
The survival of patients with ECD has improved significantly with the increasing use of targeted therapies. Certain challenges in treating ECD still remain; these challenges include delay in diagnosis and lack of access to expert ECD care, particularly for patients from underrepresented racial or socioeconomic groups. There is a lack of understanding of disparities in ECD diagnosis and treatment with respect to race and socioeconomic status. We propose a two-stage study to address these critical questions. The study will first use a multi-institutional cohort of patients with ECD to measure differences in diagnosis and treatment for patients based on their race or socioeconomic status. Next, we will expand to ECD a current program (MSK-BRIDGE) that makes it easier for patients from underrepresented groups to access expert care and clinical trials. The results from this study will identify patients with ECD who are most at risk for are having a delayed diagnosis or other disparities in their care and test the MSK-BRIDGE initiative to see if it is effective in increasing access to care for these patients. Ultimately, this study will allow clinicians and the ECD community to provide better, more equitable care for patients with the disease. The results will also lead to the development of tailored interventions for improving care for all patients with ECD.
中期报告(2026年3月)
最初的目标
Despite treatment advances, timely diagnosis and access to specialized care remain challenges for Erdheim-Chester Disease (ECD) and other histiocytic neoplasms (HN). A critical knowledge gap remains regarding disparities in ECD/HN diagnosis and treatment based on demographic factors including race, age diagnosis, and local resource level. The overarching goal of this study was to examine whether all patients with ECD and other histiocytoses are diagnosed promptly and to identify disparities in diagnosis or treatment with the aim to inform providers across the Care Center Network and promote equitable care for all patients with ECD.
The specific objectives of this study are two-fold. The first is to characterize clinical disparities in the diagnosis and treatment of patients with ECD/HN with respect to race, age at diagnosis, and local resource level by utilizing the MSK Registry and a national multi-institutional cohort.
第二个目标是试点将“MSK-BRIDGE”项目(该项目旨在为罕见癌症患者降低经济和后勤方面的障碍)的覆盖范围扩大至疑似或确诊为ECD/HN的患者。.
成就
We have thus far been able to characterize clinical disparities in the diagnosis and treatment of patients with ECD/HN with respect to race, age at diagnosis, and local resource level. We began by creating a cohort of patients seen at MSK, the University of Michigan, and the University of Alabama at Birmingham between January 2020 and December 2023 with a diagnosis of HN (including ECD, Langerhans cell histiocytosis (LCH) and Rosai-Dorfman Disease (RDD)). This cohort included 545 patients with HN from 45 states in the United States. Demographic (race, sex, zip code, and age at HN diagnosis), clinical (diagnosis subtype, date of self-reported symptom onset, date of histologic diagnosis, date of first treatment, and BRAFV600 mutational status), and treatment-related data was collected. Area Deprivation Index (ADI) was used as a validated measure of neighborhood-level resources mapped to ZIP code using indicators of income, education, employment, and housing quality.
We found that local resource level was significantly associated with the clinical trajectory of patients with HN. Patients with HN from resource-poor areas were older at diagnosis. Non-White patients and patients with RDD were more likely to live in resource-poor areas. Patients from resource-poor areas experienced a longer time from symptom onset to diagnosis. Patients from resource-poor areas were also treated sooner and with more treatment modalities than patients from resource-rich areas. Additionally. patients with ECD were more likely to experienced delayed diagnosis than patients with other HN subtypes.
我们已开始为该研究的第二个研究目标招募患者。截至目前,已有8名患者被确认为来自代表性不足群体,且可能从MSK-BRIDGE提供的援助中受益。 具体的患者援助措施包括:患者财务导航(包括交通、餐饮和/或短期住宿方面的协助);协助办理保险授权、社会保障福利或《家庭和医疗休假法》(FMLA)相关事宜;转介至“移民健康”组织以获取食品救济和补充营养援助计划(SNAP)福利;以及转介至癌症基金会申请资助。.

